Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE – Get Free Report) have received an average rating of “Buy” from the eleven brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, eight have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $66.00.
MAZE has been the topic of a number of research reports. BTIG Research reissued a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research note on Wednesday, March 25th. Mizuho raised shares of Maze Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 11th. JPMorgan Chase & Co. increased their price objective on shares of Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a research note on Tuesday, March 31st. Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Wedbush increased their price objective on shares of Maze Therapeutics from $43.00 to $58.00 and gave the company an “outperform” rating in a research note on Monday, March 16th.
View Our Latest Analysis on Maze Therapeutics
Maze Therapeutics Stock Performance
Maze Therapeutics (NASDAQ:MAZE – Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The firm had revenue of $20.00 million for the quarter. On average, sell-side analysts predict that Maze Therapeutics will post -2.73 earnings per share for the current year.
Insider Activity
In other news, SVP Amy Bachrodt sold 2,500 shares of the stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $29.44, for a total transaction of $73,600.00. Following the transaction, the senior vice president directly owned 12,965 shares in the company, valued at $381,689.60. This represents a 16.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 15,000 shares of Maze Therapeutics stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $29.46, for a total value of $441,900.00. Following the completion of the transaction, the chief marketing officer directly owned 15,000 shares in the company, valued at $441,900. This represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 102,360 shares of company stock valued at $2,722,140 in the last 90 days. Company insiders own 5.30% of the company’s stock.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of MAZE. Janus Henderson Group PLC raised its holdings in Maze Therapeutics by 318.0% in the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock valued at $130,197,000 after buying an additional 2,390,713 shares during the period. Vanguard Group Inc. raised its stake in shares of Maze Therapeutics by 218.1% during the third quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock valued at $34,615,000 after purchasing an additional 915,342 shares during the period. Marshall Wace LLP raised its stake in shares of Maze Therapeutics by 3,868.5% during the third quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock valued at $20,166,000 after purchasing an additional 758,104 shares during the period. Caligan Partners LP purchased a new stake in shares of Maze Therapeutics during the fourth quarter valued at approximately $22,794,000. Finally, ArrowMark Colorado Holdings LLC purchased a new stake in shares of Maze Therapeutics during the third quarter valued at approximately $14,135,000.
About Maze Therapeutics
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.
Featured Stories
- Five stocks we like better than Maze Therapeutics
- 3 Stocks That Could Benefit as the Robotaxi Race Heats Up
- 3 Waste Stocks Turning AI Investments into Growth
- 3 Overlooked Tech ETFs That Are Quietly Killing It This Year
- 3 ETFs Pairing Market-Beating Returns With High Dividend Yields
Receive News & Ratings for Maze Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maze Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
